In 2010, Ariad announced consequence from a phase I study of ponatinib in clients with resistant and refractory Continual myeloid leukemia and Philadelphia-beneficial acute lymphoblastic leukemia (Ph+ ALL). Disclaimer: Healthline has manufactured every single energy to help make selected that all information and facts is factually right, detailed, and up-to-day. https://jimg665xku9.wikipresses.com/user